What is interferon beta-1a used for?

It is used to reduce relapse frequency, slow disability progression and lower MRI lesion activity in relapsing multiple sclerosis, including after a first demyelinating event.

What are the most common side effects?

Flu-like symptoms (fever, chills, muscle aches), injection-site reactions, headache and fatigue are most common; liver enzyme changes, low blood counts and mood changes can also occur.

What are neutralizing antibodies?

Some people develop antibodies against interferon beta that can reduce its biological activity and potentially its clinical effect; monitoring is managed by the treating neurologist.

EMA-approvedaka Avonex, Rebif

Interferon beta-1a — Complete Research Guide (2026)

Q: How strong is the evidence?

It is strong and based on human data: multiple large randomized, double-blind, placebo-controlled trials (Jacobs 1996, PRISMS 1998, CHAMPS 2000) support its use.

Last updated 2026-06-30

TL;DR

Interferon beta-1a (also known as Avonex) is a peptide catalogued under Immune (IFN-β). Documented context: MS. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Interferon beta-1a?

Interferon beta-1a is a recombinant human interferon-beta protein marketed as Avonex (intramuscular) and Rebif (subcutaneous). It is an FDA- and EMA-approved disease-modifying therapy for relapsing forms of multiple sclerosis, including clinically isolated syndrome and relapsing-remitting disease.

The evidence base is strong and human: it rests on multiple large, randomized, double-blind, placebo-controlled trials (Jacobs 1996, PRISMS 1998, CHAMPS 2000).

How does Interferon beta-1a work?

Interferon beta binds type I interferon receptors and exerts immunomodulatory effects, shifting cytokine balance away from pro-inflammatory signaling, reducing T-cell activation and migration across the blood-brain barrier.

This dampens the inflammatory demyelination that drives multiple sclerosis relapses.

What does the research say about Interferon beta-1a?

In relapsing-remitting MS, intramuscular interferon beta-1a slowed sustained disability progression versus placebo over two years. ^[1]
Subcutaneous interferon beta-1a reduced annual relapse rate and MRI lesion burden in relapsing-remitting MS in the PRISMS trial. ^[2]
Started at a first demyelinating event, intramuscular interferon beta-1a delayed conversion to clinically definite MS (CHAMPS). ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) — Jacobs LD et al., Annals of Neurology 1996. (Randomized controlled trial (phase III))
[2] Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group — PRISMS Study Group, Lancet 1998. (Randomized controlled trial)
[3] Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis — Jacobs LD et al., The New England Journal of Medicine 2000. (Randomized controlled trial (CHAMPS))
[4] Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial — Panitch H et al., Neurology 2002. (Randomized head-to-head trial (EVIDENCE))
[5] Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results — SPECTRIMS Study Group, Neurology 2001. (Randomized controlled trial (SPECTRIMS))

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

For context only: Avonex is given as a once-weekly intramuscular injection, while Rebif is given subcutaneously three times weekly, typically with dose titration to limit flu-like effects.

Actual regimen, titration and monitoring are determined by a treating physician and are outside the scope of this encyclopedia.

Side effects & safety profile

Interferon beta-1a commonly causes flu-like symptoms (fever, chills, myalgia), injection-site reactions, headache and fatigue, which often lessen over time.

Labeling carries warnings for hepatic injury, depression and suicidality, and cytopenias; neutralizing antibodies can develop and may reduce biological efficacy.

It does not carry the interferon-alfa boxed warning, but liver enzymes, blood counts and mood should be monitored. This is a prescription biologic used only under specialist neurology supervision.

Stacking & combinations

Interferon beta-1a is a monotherapy disease-modifying drug and is not intended to be combined with other agents outside of physician-directed clinical care.

Finding Interferon beta-1a vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

Yes. It is an FDA- and EMA-approved prescription disease-modifying therapy for relapsing forms of multiple sclerosis, sold as Avonex (intramuscular) and Rebif (subcutaneous).

References

[1] Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) — Jacobs LD et al., Annals of Neurology 1996. PMID: 8602746. View sourceStudy: Randomized controlled trial (phase III)Intramuscular interferon beta-1a significantly slowed accumulation of sustained physical disability in relapsing MS.
[2] Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group — PRISMS Study Group, Lancet 1998. PMID: 9820297. View sourceStudy: Randomized controlled trialSubcutaneous interferon beta-1a reduced relapse rate, disability progression and MRI lesion activity in relapsing-remitting MS.
[3] Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis — Jacobs LD et al., The New England Journal of Medicine 2000. PMID: 11006365. View sourceStudy: Randomized controlled trial (CHAMPS)Early interferon beta-1a after a first demyelinating event reduced the rate of conversion to clinically definite MS.
[4] Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial — Panitch H et al., Neurology 2002. PMID: 12451188. View sourceStudy: Randomized head-to-head trial (EVIDENCE)Higher-dose, more frequent subcutaneous interferon beta-1a outperformed once-weekly intramuscular dosing on relapse and MRI outcomes at 24 weeks.
[5] Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results — SPECTRIMS Study Group, Neurology 2001. PMID: 11402106. View sourceStudy: Randomized controlled trial (SPECTRIMS)In secondary progressive MS, subcutaneous interferon beta-1a reduced relapses but did not significantly delay disability progression.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.